other-cancer

Six Src inhibitors tested in mouth cancer reveal why monotherapy keeps failing — and how to fix it

Oral squamous cell carcinoma (OSCC) is a deadly head and neck cancer with limited systemic treatment options. The kinase Src sits at the intersection of multiple cancer-driving pathways and has long been a therapeutic target, but Src inhibitors have underperformed in clinical trials. This study systematically screened six different Src inhibitors across seven human OSCC cell lines to understand why.

The team found highly heterogeneous sensitivity — different cell lines responded very differently to each drug — and traced this variability to diverse patterns of active oncogenic signaling. This means one-size-fits-all Src inhibition is unlikely to work, but targeted combinations matching inhibitor to the specific activated pathways in a given tumor might.

The study also identified combinatorial strategies that might overcome resistance, pointing toward biomarker-driven patient selection as the key to making Src inhibitors clinically useful in OSCC.

Key Findings

Six Src inhibitors (dasatinib, ponatinib, vandetanib, saracatinib, PP2, bosutinib) showed heterogeneous efficacy across seven OSCC cell lines
Variable sensitivity correlated with differential activation of major oncogenic signaling pathways
Src inhibitor monotherapy is insufficient due to pathway diversity across tumors
Combinatorial approaches may overcome heterogeneous resistance
Findings support biomarker-driven patient stratification for Src inhibitor trials

Implications

This work directly explains historical clinical failures of Src inhibitors in OSCC and provides a rational basis for combination strategies. It also has implications for other squamous cell carcinomas where Src is active.

Caveats

Preprint — not peer reviewed. Cell line study only — patient-derived models or in vivo validation not described in abstract. Seven cell lines may not capture the full genomic diversity of OSCC. Cisplatin resistance interactions need further study.

Source: bioRxiv — 2026-04-09

Landmark DCIS trial, CRC microbiome & AML combos

Two themes cut across this week’s 236 posts. The first is de-escalation: researchers are building rigorous evidence that patients can safely do less — skip lymph node surgery, forgo radiotherapy, watch pre-invasive lesions instead of cutting them out. The landmark result here is a randomized trial confirming that active surveillance

Colorectal Cancer Microbiome Discovery Platform

Analysis of 9,000+ patients revealed that only colorectal cancer — not other cancer types — consistently harbors distinct microbial communities, suggesting the gut microbiome has a unique relationship with colorectal carcinogenesis that could be exploited for diagnostics and treatment.

GBM Tumor Microenvironment Drug Target Atlas

Non-cancerous brain support cells were found to promote glioblastoma growth through paracrine signaling, and blocking this communication dramatically slowed tumor growth — revealing that GBM's microenvironment contains targetable vulnerabilities that are being systematically overlooked by drug…

BET Inhibitor Target Selectivity Database

BRD2 and BRD4 have fundamentally distinct functions — BRD2 prepares genes for activation while BRD4 triggers transcription — meaning that pan-BET inhibitors have been disrupting gene regulation in counterproductive ways, and the field now needs selective BRD4 inhibitors.